Pharmaceutical Medicine
ISSN:1178-2595

Pharmaceutical Medicine

PHARM MED
学科领域:医学
是否预警:不在预警名单内
是否OA:
录用周期:-
新锐分区:医学3区
年发文量:32
影响因子:4.5
JCR分区:Q1

基本信息

制药医学是一门专业学科,涉及药物、药物-器械和药物-诊断组合的发现、开发、评价、注册、监管、监测、营销、分销和定价等医学方面。《日刊》传播信息,以支持从事这些高度相关职能的专业人员。重点领域包括转化医学、临床试验设计、药物警戒、临床毒理学、药物监管、临床药理学、生物统计学和药物经济学。期刊内容包括:有争议的或新出现的问题的概述。提供关于主题问题的权威信息来源的综合性叙述性综述。使用PRISMA声明中概述的明确、系统的方法,整理经验证据以回答特定研究问题的系统性综述。报告精心设计的研究结果的原创研究文章,与更广泛的临床研究领域有很强的联系。其他数字功能(包括动画摘要、视频摘要、幻灯片、音频幻灯片、教学视频、信息图表、播客和动画)可以与文章一起发表;目的是提高刊物的知名度、读者群和教育价值。此外,发表在《药物医学》上的文章可能会附有简明扼要的摘要,以帮助对该领域有一定了解但没有深入专业知识的读者了解重要的医学进展。所有稿件都要经过国际专家的同行评审。欢迎给编辑写信,并将考虑出版。
1178-2595ESCI/Scopus收录
4.5
0
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学3区
PHARMACOLOGY & PHARMACY 药学
3区
N/A
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科:PHARMACOLOGY & PHARMACY
ESCI
Q1
64/352
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科:PHARMACOLOGY & PHARMACY
ESCI
Q2
150/353
暂无h-index数据
32
1%---PHARMACOLOGY & PHARMACY-
4.4%
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
78.13%43.56%-
CiteScore:5.50
SJR:1.112
SNIP:1.178
学科类别分区排名百分位
大类:Medicine
小类:Pharmacology (medical)
Q2
84 / 275
大类:Medicine
小类:Pharmacology
Q2
127 / 321

期刊高被引文献

Nutraceuticals: Reviewing their Role in Chronic Disease Prevention and Management
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00289-w
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00305-z
ICD-11: Impact on Traditional Chinese Medicine and World Healthcare Systems
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00295-y
Lay Summaries of Clinical Study Results: An Overview
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00285-0
Combined Liquid Chromatography-mass Spectrometry and Next-generation DNA Sequencing Detection of Adulterants and Contaminants in Analgesic and Anti-inflammatory Herbal Medicines
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00314-y
Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00269-0
Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00288-x
Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00307-x
The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00309-9
A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00267-2
Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00279-y
Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00274-3
Agomelatine Drug Utilisation Study in Selected European Countries: A Multinational, Observational Study to Assess Effectiveness of Risk-Minimisation Measures
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00291-2
Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00280-5
Evaluation of Physician Knowledge of the Key Safety Information for Aflibercept in Canada: Evaluation of Risk-Minimization Measures
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00278-z
Effectiveness of Risk Minimization Measures to Prevent Pregnancy Exposure to Mycophenolate-Containing Medicines in Europe
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00304-0
Adverse Drug Reaction Risk Measures: A Comparison of Estimates from Drug Surveillance and Randomised Trials
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00287-y
Association of Adverse Drug Events with Hospitalization Outcomes and Costs in Older Adults in the USA using the Nationwide Readmissions Database
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00286-z
Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00270-7
Including Traditional Chinese Medicine Diagnoses in ICD-11 May Not Advance the Evaluation of Traditional Chinese Medicine Therapies
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00297-w
ITS2: An Ideal DNA Barcode for the Arid Medicinal Plant Rhazya Stricta
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00266-3
Current Landscape of Late-Phase Clinical Trials for Alzheimer’s Disease: Comparing Regional Variation Between Subjects in Japan and North America
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00306-y
Genome Editing: Promoting Responsible Research
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00276-1
Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00317-9
Evaluation of the Implementation of Additional Risk Minimization Activities in Europe, the USA, and Japan
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00303-1
Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation?
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00302-2
Major Pharmaceutical Conferences and Courses
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00312-0
Danish Physicians’ Views on the Appropriateness of the Involvement of Patients with Type 2 Diabetes in Regulatory Decision Making: A Qualitative Study
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00275-2
Forum
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00301-3
Design and Analysis of Biosimilar Switching Studies
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00296-x
Forum
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00321-z
Correction to: Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00319-7
Liver Test Monitoring: Real-World Compliance for Drugs with Monitoring Requirements at 2-Week Intervals or More Frequently
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00294-z
The Pharmaceutical Year That Was, 2019
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00313-z
Forum
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00311-1
Forum
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00283-2
Major Pharmaceutical Conferences and Courses
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00290-3
Major Pharmaceutical Conferences and Courses
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00300-4
Forum
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00271-6
Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00281-4
Factors Influencing the Generation of Evidence from Simple Data Held in International Rare Disease Patient Registries
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00316-w

相关文章

2026年3月发布(新锐分区)
大类学科小类学科Top期刊综述期刊
医学3区
PHARMACOLOGY & PHARMACY 药学
3区
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学4区
PHARMACOLOGY & PHARMACY 药学
4区